Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Jan 14, 1998
Hawthorne, NY and Dublin, Ireland (January 14, 1998) --- Emisphere Technologies, Inc. (Nasdaq: EMIS) and Elan Corporation, plc (NYSE: ELN) announced today on behalf of their joint venture the successful completion of two Phase I clinical trials for its oral formulation of heparin. These are the third and fourth Phase I clinical trials for the oral ...
Mar 16, 1998
Hawthorne, NY and Indianapolis IN, March 16, 1998 --- Emisphere Technologies, Inc. (Nasdaq NMS: EMIS) and Eli Lilly & Co. (NYSE:LLY) announced today that Lilly has executed two license agreements with Emisphere to utilize Emisphere's proprietary oral delivery technology to create oral forms of two of Lilly's therapeutic proteins. One compound i...
Mar 19, 1998
Hawthorne, NY, March 19, 1998 --- Emisphere Technologies, Inc. (Nasdaq: NMS:EMIS) today reported a net loss of approximately $2.6 million, or $0.25 per share, for the second quarter ended January 31, 1998, as compared to net loss of approximately $2.4 million, or $0.26 per share, for the same period last year. The Company also reported a net loss o...
May 4, 1998
Hawthorne, NY, May 4, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced the closing of a $13.5 million private placement of 5% senior convertible notes. Emisphere plans to use the proceeds of the private placement for general purposes, including funding its share of the clinical trials for its oral heparin product. The note...
May 20, 1998
Hawthorne, NY, May 20, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Barry B. Kanarek, M.D., Ph.D., has joined the Company as Senior Vice President of Clinical Affairs, a newly created position. Dr. Kanarek will be responsible for the directing, planning, executing and interpreting of clinical trials/research and data co...
May 27, 1998
Hawthorne, NY, May 27, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) announced today it has initiated a Phase II clinical study for its oral heparin product for the prevention of deep vein thrombosis. The study will have three arms of approximately 40 patients each who have undergone surgery for hip replacement, and will be conducted at up t...
Jun 15, 1998
Hawthorne, NY, June 15, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today reported net income of $1.3 million, or $0.10 per diluted share, for the third quarter ended April 30, 1998, compared to a net loss of $2.1 million, or $0.22 per share, for the third quarter last year. The Company also reported a net loss of $3.7 million, or $0.35 pe...
Aug 5, 1998
Tarrytown, NY, August 5, 1998 --- Emisphere Technologies, Inc. (Nasdaq NMS: EMIS) announced today that Emisphere and Elan Corporation plc have contributed $10 million ($5 million each) to their 50-50 joint venture to develop oral formulations of heparin compounds. The joint venture is currently conducting a Phase II trial for an oral formulation of...
Sep 3, 1998
Indianapolis, IN, and Tarrytown, NY September 3, 1998 --- Eli Lilly & Co. (NYSE: LLY) and Emisphere Technologies, Inc. (Nasdaq: NMS: EMIS) announced today that Lilly has formally selected a proprietary Emisphere carrier for clinical testing of the oral delivery of an important Lilly protein for the treatment of Osteoporosis. Preparations for cl...
Oct 27, 1998
Hawthorne, NY, October 27, 1998 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today reported fourth quarter and year end financial results for the period ended July 31, 1998. Net loss for the fourth quarter of 1998 was $3.4 million, or $0.31 per diluted share, compared to a net loss of $1.8 million, or $0.19 per share, in the fourth quarte...
Jan 11, 1999
Hawthorne, NY and Dublin, Ireland, January 11, 1999 --- Emisphere Technologies, Inc. (Nasdaq: NMS: EMIS) and Elan Corporation, plc (NYSE: ELN) announced that the preliminary results of the Phase II oral heparin study indicated that the oral heparin formulations were comparable to injectable heparin in thc prevention of deep venous thrombosis (DVT)...
Jan 13, 1999
Tarrytown, NY and Dublin, Ireland, January 13, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that it will form a new subsidiary company to explore the development of a novel drug design technology. The Company will initially investigate the use of the technology for the treatment of drug-resistant microbial infections. The Ch...
Feb 25, 1999
Tarrytown, NY, February 25, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today reported on a number of key events in their oral heparin program. First, the manufacturing process for the Emisphere carrier has been successfully taken to a larger scale with greater overall purity, and significantly lower cost than the pilot scale process. Seco...
Mar 13, 1999
Tarrytown, NY and Dublin, Ireland, March 17, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today reported financial results for the second quarter and six months ended January 31, 1999. For the second quarter of 1999, Emisphere reported a net loss of approximately $5.1 million, or $0.45 per share, as compared to a net loss of approxim...
Apr 13, 1999
Tarrytown, NY, April 13, 1999 --- Emisphere Technologies, Inc. (Nasdaq: EMIS) today announced that Charles H. Abdalian, Jr. has joined the Company as Chief Financial Officer, a newly created position, and that Steven M. Dinh, Sc.D. has been hired as Vice President of Research for Emisphere Technologies. Both individuals will be reporting to Michae...
Page:
2
...
28
Next Last
 

= add release to Briefcase

FOLLOW US